Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Operating Leases for 7 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases changed 0.03% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, changed 0.03% year-over-year, with the annual reading at $3.5 million for FY2025, 0.03% changed from the prior year.
  • Operating Leases for Q4 2025 was $3.5 million at Akebia Therapeutics, down from $4.9 million in the prior quarter.
  • The five-year high for Operating Leases was $37.7 million in Q1 2022, with the low at $2.1 million in Q1 2025.
  • Average Operating Leases over 5 years is $18.1 million, with a median of $15.7 million recorded in 2023.
  • The sharpest move saw Operating Leases surged 62.52% in 2022, then plummeted 83.29% in 2025.
  • Over 5 years, Operating Leases stood at $33.7 million in 2021, then fell by 14.07% to $29.0 million in 2022, then tumbled by 69.11% to $8.9 million in 2023, then tumbled by 60.36% to $3.5 million in 2024, then grew by 0.03% to $3.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $3.5 million, $4.9 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.